AAPL289.85+0.49 (+0.17%) ▲|ABBV249.67-1.97 (-0.78%) ▼|ABT92.66+1.92 (+2.11%) ▲|ACN126.81+2.37 (+1.90%) ▲|ADBE208.69+3.67 (+1.79%) ▲|AMAT688.39-34.62 (-4.79%) ▼|AMD560.27-20.64 (-3.55%) ▼|AMGN362.83+0.71 (+0.19%) ▲|AMT165.40+1.83 (+1.12%) ▲|AMZN236.24-2.11 (-0.88%) ▼|AVGO370.19-7.56 (-2.00%) ▼|AXP339.32+1.07 (+0.32%) ▲|BA218.29+1.82 (+0.84%) ▲|BAC57.45+0.47 (+0.82%) ▲|BKNG180.02+1.78 (+1.00%) ▲|BLK964.15+2.59 (+0.27%) ▲|BMY57.22-0.40 (-0.69%) ▼|BNY145.09+0.48 (+0.33%) ▲|BRK-B500.49+0.10 (+0.02%) ▲|C139.12-0.84 (-0.60%) ▼|CAT1,038.13-26.77 (-2.51%) ▼|CL91.78+0.10 (+0.11%) ▲|CMCSA24.00-0.56 (-2.26%) ▼|COF202.06+1.44 (+0.72%) ▲|COP104.00+0.04 (+0.04%) ▲|COST925.00-10.47 (-1.12%) ▼|CRM163.56+6.90 (+4.40%) ▲|CSCO116.72-0.74 (-0.63%) ▼|CVS103.58+0.13 (+0.13%) ▲|CVX166.48+0.72 (+0.43%) ▲|DE625.06-9.27 (-1.46%) ▼|DHR191.76+1.28 (+0.67%) ▲|DIS97.00+0.75 (+0.77%) ▲|DUK126.33-0.25 (-0.20%) ▼|EMR141.55-1.61 (-1.12%) ▼|FDX315.28+2.15 (+0.69%) ▲|GD359.74+5.50 (+1.55%) ▲|GE374.75+1.02 (+0.27%) ▲|GEV1,151.69-23.17 (-1.97%) ▼|GILD125.78-0.56 (-0.44%) ▼|GM77.20+0.12 (+0.16%) ▲|GOOG353.82+0.49 (+0.14%) ▲|GOOGL357.16-0.22 (-0.06%) ▼|GS1,016.00+4.63 (+0.46%) ▲|HD354.31+1.63 (+0.46%) ▲|HON224.85+0.95 (+0.42%) ▲|IBM286.68+5.47 (+1.95%) ▲|INTC135.25-4.38 (-3.14%) ▼|INTU270.82+9.82 (+3.76%) ▲|ISRG401.82+4.14 (+1.04%) ▲|JNJ252.95-1.02 (-0.40%) ▼|JPM328.29+0.96 (+0.29%) ▲|KO81.62+0.35 (+0.42%) ▲|LIN519.07+0.13 (+0.02%) ▲|LLY1,195.38-4.05 (-0.34%) ▼|LMT518.83+9.37 (+1.84%) ▲|LOW223.16+2.67 (+1.21%) ▲|LRCX408.21-25.12 (-5.80%) ▼|MA514.50+0.90 (+0.18%) ▲|MCD269.55-0.76 (-0.28%) ▼|MDLZ58.72+0.88 (+1.52%) ▲|MDT79.54+1.31 (+1.67%) ▲|META604.43+41.14 (+7.30%) ▲|MMM160.68-1.23 (-0.76%) ▼|MO72.15+0.20 (+0.28%) ▲|MRK126.86-1.64 (-1.28%) ▼|MS209.85+0.81 (+0.39%) ▲|MSFT376.53+3.51 (+0.94%) ▲|MU1,089.58-64.71 (-5.61%) ▼|NEE87.36-0.37 (-0.42%) ▼|NFLX72.72+1.32 (+1.85%) ▲|NKE42.12+1.08 (+2.62%) ▲|NOW102.66+3.39 (+3.41%) ▲|NVDA195.25-4.84 (-2.42%) ▼|ORCL145.70-0.96 (-0.65%) ▼|PEP139.18+3.78 (+2.79%) ▲|PFE24.11+0.33 (+1.37%) ▲|PG146.41-0.11 (-0.08%) ▼|PLTR123.25+6.58 (+5.64%) ▲|PM179.11-1.74 (-0.96%) ▼|QCOM184.51-0.29 (-0.15%) ▼|RTX189.98+0.32 (+0.17%) ▲|SBUX102.45+0.26 (+0.25%) ▲|SCHW93.35+1.15 (+1.25%) ▲|SO95.66-0.03 (-0.03%) ▼|SPG221.57-2.15 (-0.96%) ▼|T20.81+0.12 (+0.56%) ▲|TMO505.28+4.37 (+0.87%) ▲|TMUS170.88+3.15 (+1.88%) ▲|TSLA422.87+2.27 (+0.54%) ▲|TXN302.33+4.26 (+1.43%) ▲|UBER72.75+0.64 (+0.89%) ▲|UNH418.13+2.78 (+0.67%) ▲|UNP272.74+0.84 (+0.31%) ▲|UPS108.25+0.85 (+0.79%) ▲|USB60.96+0.55 (+0.90%) ▲|V342.20-0.39 (-0.11%) ▼|VZ42.38+0.07 (+0.17%) ▲|WFC84.21+1.57 (+1.90%) ▲|WMT107.91-5.35 (-4.72%) ▼|XOM137.00+0.52 (+0.38%) ▲|AAPL289.85+0.49 (+0.17%) ▲|ABBV249.67-1.97 (-0.78%) ▼|ABT92.66+1.92 (+2.11%) ▲|ACN126.81+2.37 (+1.90%) ▲|ADBE208.69+3.67 (+1.79%) ▲|AMAT688.39-34.62 (-4.79%) ▼|AMD560.27-20.64 (-3.55%) ▼|AMGN362.83+0.71 (+0.19%) ▲|AMT165.40+1.83 (+1.12%) ▲|AMZN236.24-2.11 (-0.88%) ▼|AVGO370.19-7.56 (-2.00%) ▼|AXP339.32+1.07 (+0.32%) ▲|BA218.29+1.82 (+0.84%) ▲|BAC57.45+0.47 (+0.82%) ▲|BKNG180.02+1.78 (+1.00%) ▲|BLK964.15+2.59 (+0.27%) ▲|BMY57.22-0.40 (-0.69%) ▼|BNY145.09+0.48 (+0.33%) ▲|BRK-B500.49+0.10 (+0.02%) ▲|C139.12-0.84 (-0.60%) ▼|CAT1,038.13-26.77 (-2.51%) ▼|CL91.78+0.10 (+0.11%) ▲|CMCSA24.00-0.56 (-2.26%) ▼|COF202.06+1.44 (+0.72%) ▲|COP104.00+0.04 (+0.04%) ▲|COST925.00-10.47 (-1.12%) ▼|CRM163.56+6.90 (+4.40%) ▲|CSCO116.72-0.74 (-0.63%) ▼|CVS103.58+0.13 (+0.13%) ▲|CVX166.48+0.72 (+0.43%) ▲|DE625.06-9.27 (-1.46%) ▼|DHR191.76+1.28 (+0.67%) ▲|DIS97.00+0.75 (+0.77%) ▲|DUK126.33-0.25 (-0.20%) ▼|EMR141.55-1.61 (-1.12%) ▼|FDX315.28+2.15 (+0.69%) ▲|GD359.74+5.50 (+1.55%) ▲|GE374.75+1.02 (+0.27%) ▲|GEV1,151.69-23.17 (-1.97%) ▼|GILD125.78-0.56 (-0.44%) ▼|GM77.20+0.12 (+0.16%) ▲|GOOG353.82+0.49 (+0.14%) ▲|GOOGL357.16-0.22 (-0.06%) ▼|GS1,016.00+4.63 (+0.46%) ▲|HD354.31+1.63 (+0.46%) ▲|HON224.85+0.95 (+0.42%) ▲|IBM286.68+5.47 (+1.95%) ▲|INTC135.25-4.38 (-3.14%) ▼|INTU270.82+9.82 (+3.76%) ▲|ISRG401.82+4.14 (+1.04%) ▲|JNJ252.95-1.02 (-0.40%) ▼|JPM328.29+0.96 (+0.29%) ▲|KO81.62+0.35 (+0.42%) ▲|LIN519.07+0.13 (+0.02%) ▲|LLY1,195.38-4.05 (-0.34%) ▼|LMT518.83+9.37 (+1.84%) ▲|LOW223.16+2.67 (+1.21%) ▲|LRCX408.21-25.12 (-5.80%) ▼|MA514.50+0.90 (+0.18%) ▲|MCD269.55-0.76 (-0.28%) ▼|MDLZ58.72+0.88 (+1.52%) ▲|MDT79.54+1.31 (+1.67%) ▲|META604.43+41.14 (+7.30%) ▲|MMM160.68-1.23 (-0.76%) ▼|MO72.15+0.20 (+0.28%) ▲|MRK126.86-1.64 (-1.28%) ▼|MS209.85+0.81 (+0.39%) ▲|MSFT376.53+3.51 (+0.94%) ▲|MU1,089.58-64.71 (-5.61%) ▼|NEE87.36-0.37 (-0.42%) ▼|NFLX72.72+1.32 (+1.85%) ▲|NKE42.12+1.08 (+2.62%) ▲|NOW102.66+3.39 (+3.41%) ▲|NVDA195.25-4.84 (-2.42%) ▼|ORCL145.70-0.96 (-0.65%) ▼|PEP139.18+3.78 (+2.79%) ▲|PFE24.11+0.33 (+1.37%) ▲|PG146.41-0.11 (-0.08%) ▼|PLTR123.25+6.58 (+5.64%) ▲|PM179.11-1.74 (-0.96%) ▼|QCOM184.51-0.29 (-0.15%) ▼|RTX189.98+0.32 (+0.17%) ▲|SBUX102.45+0.26 (+0.25%) ▲|SCHW93.35+1.15 (+1.25%) ▲|SO95.66-0.03 (-0.03%) ▼|SPG221.57-2.15 (-0.96%) ▼|T20.81+0.12 (+0.56%) ▲|TMO505.28+4.37 (+0.87%) ▲|TMUS170.88+3.15 (+1.88%) ▲|TSLA422.87+2.27 (+0.54%) ▲|TXN302.33+4.26 (+1.43%) ▲|UBER72.75+0.64 (+0.89%) ▲|UNH418.13+2.78 (+0.67%) ▲|UNP272.74+0.84 (+0.31%) ▲|UPS108.25+0.85 (+0.79%) ▲|USB60.96+0.55 (+0.90%) ▲|V342.20-0.39 (-0.11%) ▼|VZ42.38+0.07 (+0.17%) ▲|WFC84.21+1.57 (+1.90%) ▲|WMT107.91-5.35 (-4.72%) ▼|XOM137.00+0.52 (+0.38%) ▲|

29 C

New York

Wednesday, July 1, 2026

Group 1 Automotive Continues Nationwide Brand Alignment with Group 1 Honda South San Antonio in south San Antonio

Bluprynt and Chainproof Launch ‘Verified D&O’ Insurance for the Digital Asset Economy

Profound Launches the Profound Index at Zero Click New York, Creating the Definitive Benchmark for AI Search Visibility

Tag: patients

Galapagos Appoints Aaron Cox as Chief Financial Officer

Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine’s DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

McLaren Health Care Data Breach Alert Issued By Wolf Haldenstein

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study found that oral semaglutide offers meaningful cardiovascular benefits...

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data...

Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A, with or without inhibitors¹. Additionally, a FRONTIER5 Patient-Reported Outcomes (PROs) assessment found the Mim8 pen-injector easy to use, with an overall strong user preference for the pen-injector compared to the previous emicizumab injection system^2,3. The results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, D.C.

Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the...

New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy

Once-weekly insulin helped patients achieve an average A1C of 6.92% in QWINT-1 trial Results support once-weekly insulin as effective alternative to daily treatment CHICAGO, June 22,...

Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes

Findings Highlight Potential for Novel Approach to Insulin Delivery in Pediatric Population CHICAGO, June 22, 2025 /PRNewswire/ -- Today, a new study demonstrates inhaled insulin...

ROSEN, A HIGHLY RANKED LAW FIRM, Encourages Elevance Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELV

NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline.

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. ("PepGen" or the "Company")...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsPatients